hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06362148 id: 1-10-72-134-23 briefTitle: Circulating Tumor DNA in Peripheral T-cell Lymphomas acronym: CIRCULATE overallStatus: RECRUITING date: 2024-03-01 date: 2026-12-31 date: 2030-12 date: 2024-04-12 date: 2024-04-22 name: University of Aarhus class: OTHER name: Aarhus University Hospital briefSummary: The aim of this study is to evaluate the feasibility of circulating tumor DNA (ctDNA) measurement in blood plasma for the applicability in prognostication, treatment evaluation and measurable residual disease (MRD) surveillance in a cohort of patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphomas (PTCL). conditions: Peripheral T-cell Lymphoma conditions: NK/T-Cell Lymphoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay name: 18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) measure: ctDNA occurrence measure: ctDNA quantification measure: Progression free survival measure: Overall survival measure: Radiographic assessment by PET/CT measure: Comparison of molecular and radiographic response measure: Spatial and temporal mutational homo- or heterogeneity measure: Fragment pattern analysis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Hematology, Aarhus University Hospital status: RECRUITING city: Aarhus state: Central Denmark Region zip: 8200 country: Denmark name: Patrick R Noerhave, MD role: CONTACT phone: +4551543715 email: panoer@rm.dk name: Francesco A d'Amore, MD, DMSc role: CONTACT phone: +4523708527 email: frandamo@rm.dk name: Patrick R Noerhave, MD role: PRINCIPAL_INVESTIGATOR name: Martin B Pedersen, MD, PhD role: SUB_INVESTIGATOR name: Francesco A d'Amore, MD, DMSc role: SUB_INVESTIGATOR lat: 56.15674 lon: 10.21076 hasResults: False
nctId: NCT06362135 id: 0733 briefTitle: Virtual Home Visits for Stroke Patients and Their Caregivers acronym: INHABASAEV overallStatus: RECRUITING date: 2023-08-01 date: 2024-12-01 date: 2025-03-01 date: 2024-04-12 date: 2024-04-15 name: The Scientific and Technological Research Council of Turkey class: OTHER briefSummary: The primary aim of this study is to evaluate the effectiveness of virtual home care for stroke patients and their caregivers. The secondary purpose is to evaluate the usability of the application by developing a mobile application for use in virtual home visits.
The study will be carried out using the mixed research model, in which quantitative and qualitative methods are used together. The population of the research will consist of patients and caregivers with the diagnosis of hemorrhage, infarction, cerebrovascular accident and cerebral infarction, who applied to the Antalya Provincial Health Directorate Antalya Training and Research Hospital Home Health Unit, where the study is planned to be conducted. The sample of the study will consist of stroke patients and caregivers who meet the criteria for inclusion in the study. The first phase of the study was designed as a parallel group, single center and single blind randomized controlled trial to evaluate the effectiveness of virtual home visits in terms of time, cost and caregiver competence. The experimental group was the patient/patient relative group who made a virtual home visit, the control group will consist of 48 patients/patient relatives who have been visited face-to-face. In the second phase of the study, semi-structured interview method will be used to determine the views of patients/patient relatives about virtual home visits. In order to evaluate the usability of the developed application, a usability survey will be applied to the group that has visited the virtual home.
With the results of this study, telemedicine applications in home care services will help to increase accessibility to home care services and reduce health care costs.considered to contribute. At the same time, it is expected that the results of the study will contribute to the scientific literature in the field of design and application of telemedicine services, which are developing and spreading conditions: Stroke conditions: Caregiver conditions: Virtual conditions: Home Visit studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Assignment Virtual visit with stroke patient and their caregiver primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE maskingDescription: Telephone support or virtual meeting during the research process will be provided by an independent interviewer. whoMasked: OUTCOMES_ASSESSOR count: 96 type: ESTIMATED name: Virtual Home Visit name: Control Group measure: Effect of Virtual and Face to face to home visit measure: Level of competence of stroke caregiver measure: Frequency of unplanned hospital readmission measure: Effect of the virtual home visit sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yasemin Demi̇r Avci̇ status: RECRUITING city: Antalya zip: 07058 country: Turkey name: Yasemin Demir Avcı, PhD role: CONTACT phone: +905514028492 email: ydemir@akdeniz.edu.tr lat: 36.90812 lon: 30.69556 hasResults: False
nctId: NCT06362122 id: PREDICTO-POLYP briefTitle: Anatomo-clinico-biological Profiles in Severe Nasal Polyps overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-04-01 date: 2026-10-01 date: 2024-04-12 date: 2024-04-12 name: Poitiers University Hospital class: OTHER briefSummary: Nasal sinus polyposis is a chronic inflammatory pathology of the nasal cavity and sinus cavities that causes bilateral and multifocal polyp development and has a prevalence of 2 to 4% in the general population.
Therapeutic management consists of first-line medical treatment for anti-inflammatory purposes. Local corticosteroid therapy, using nasal sprays, is the background treatment. Surgical management is offered to patients in case of failure of medical treatment. Although effective, surgery does not protect patients from recurrence of symptoms related to regrowth of polyps. Recently, biologics have appeared, which despite its effectiveness, about 20% of patients have a partial or no response to these treatments. There is currently no possibility of determining the probability of response to treatments in patients.
It is therefore essential to determine an anatomo-clinico-biological correlation associating the anatomopathological profile, the clinical characteristics and the cytokine signature in order to best guide the patient's management, including the initiation of biotherapy. Indeed, patients, according to their clinical, biological characteristics and the cytokine signature of their polyps will react differently to different treatments, including surgery and biotherapy. This correlation will serve as a predictor of treatment response. conditions: NASAL POLYPS studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 200 type: ESTIMATED name: identification anatomo-clinico-biological profiles measure: Identify anatomical profiles present in nasal sinus polyposis resistant to medical treatment. measure: Evaluation of symptoms related to nasal sinus polyposis by visual analogue scale measure: Evaluation to quality of life by Sino-Nasal Outcome Test measure: Identify biological profiles for patients with nasal sinus polyposis measure: Evaluation to cytokine concentration in serum for patients with nasal sinus polyposis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06362109 id: Once tubefeeding briefTitle: The Impact of Intermittent Nutritional Tube Supplementation in Elderly Patients With Dysphagia overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2024-12 date: 2024-04-12 date: 2024-04-12 name: Zhao Song Ling class: OTHER_GOV briefSummary: This is a prospective, randomized controlled clinical trail involved Elderly Patients With Dysphagia.The goal of this clinical trial is to compare the clinical effect of Intermittent Oro-esophageal Tube Feeding in Elderly Patients With Dysphagia. The main questions it aims to answer:
Participants will be divided into two groups randomly. All patients are given routine rehabilitation and the intervention group is given Intermittent Oro-esophageal Tube Feeding once a day. conditions: Dysphagia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Routine rehabilitation name: Intermittent Oro-esophageal Tube Feeding measure: Nutritional status-prealbumin measure: Nutritional status-albumin measure: Nutritional status-hemoglobin sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06362096 id: pyrotinib diarrhra briefTitle: A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2026-05 date: 2024-04-12 date: 2024-04-12 name: Huihua Xiong class: OTHER briefSummary: To explore a reasonable and effective way to reduce the incidence of grade 3 or above diarrhea caused by pyrotinib conditions: Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 72 type: ESTIMATED name: Trastuzumab+pyrotinib+taxene measure: Incidence of ≥ grade 3 diarrhea sex: ALL minimumAge: 17 Years maximumAge: 75 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06362083 id: 34-317 ex 21/22 briefTitle: Urethral Stricture Database overallStatus: RECRUITING date: 2024-01-15 date: 2034-01-15 date: 2034-03-15 date: 2024-04-12 date: 2024-04-12 name: Medical University of Graz class: OTHER briefSummary: Establishment of a clinical urethral stricture database for a prospective longitudinal cohort study. conditions: Urethral Stricture studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: Questionnaires and data collection measure: Success rate of urethral reconstructive surgeries measure: Complications of urethral reconstructive surgeries measure: Sexual function after urethral reconstructive surgeries measure: Health status after urethral reconstructive surgeries sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Röthl Martina Anna status: RECRUITING city: Graz state: Styria zip: 8036 country: Austria name: Marianne Leitsmann, Prof. Dr. role: CONTACT phone: +43 316 385 80550 email: martina.roethl@medunigraz.at name: Marianne Leitsmann, Prof. Dr. role: PRINCIPAL_INVESTIGATOR lat: 47.06667 lon: 15.45 hasResults: False
nctId: NCT06362070 id: COMPAR-G briefTitle: Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Gastrectomy overallStatus: RECRUITING date: 2024-01-31 date: 2024-03-30 date: 2025-07-31 date: 2024-04-12 date: 2024-04-12 name: Azienda Ospedaliera Universitaria Integrata Verona class: OTHER briefSummary: The object of this exploratory clinical trial is to evaluate intra and post-operative complications in a population that underwent Robotic Gastrectomy, with multiple platforms:
3. surgery with the Versius platform. conditions: Gastric Cancer conditions: Gastrointestinal Cancer conditions: Neoplasms conditions: Gastric Diffuse Adenocarcinoma conditions: Gastric Neoplasm conditions: Stomach Adenocarcinoma studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 75 type: ESTIMATED name: DaVinci® Surgical System name: Hugo™ RAS System name: Versius® Robotic Surgery System measure: Conversion rate to open or laparoscopic approach (Phase 1) measure: Number of participants with major intraoperative complications (Phase 1) measure: Evaluation of surgical times of the standardized procedures (Phase 2) measure: Analysis of video of surgical procedures (Phase 2) measure: Estimated Blood Loss measure: Overall duration of the surgery measure: Anesthesia, Lymphadenectomy, Gastrectomy (10 different surgical steps) measure: Number of participants with major postoperative complications measure: Compliance rate to ERAS protocol measure: Postoperative hospitalization measure: Postoperative pain measure: Re-admission rate to hospitalization measure: Damage due to positioning measure: Positive Surgical Margin measure: Lymph nodes resection measure: Quality of Life Evaluation measure: Time taken for platform-related technical steps measure: Possible malfunction of the platform measure: Non-Technical Skills Assessment (NTS) demonstrated by members of the surgical team during the intraoperative phase. measure: Procedure-related costs sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: General and Upper GI Unit status: RECRUITING city: Verona zip: 37126 country: Italy name: Simone SG Giacopuzzi, MD, Prof role: CONTACT phone: +39 0458127510 email: simone.giacopuzzi@univr.it name: Simone Giacopuzzi, MD, Prof role: PRINCIPAL_INVESTIGATOR name: Maria Bencivenga, MD, Prof role: SUB_INVESTIGATOR lat: 45.4299 lon: 10.98444 hasResults: False
nctId: NCT06362057 id: ADMNF-0020324 briefTitle: Biomechanical Effects of Digitally Constructed Subperiosteal Implants overallStatus: RECRUITING date: 2024-04-04 date: 2024-06-20 date: 2024-07-27 date: 2024-04-12 date: 2024-04-12 name: Menoufia University class: OTHER briefSummary: Subperiosteal implants were first introduced in 1940 and then used worldwide for the treatment of edentulous maxilla or mandible with advanced bone atrophy. conditions: Bone Loss studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 9 type: ESTIMATED name: Subperiosteal implant framework measure: bone loss under the implants sex: ALL minimumAge: 30 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mohammed A. El-Sawy status: RECRUITING city: Mansoura zip: 12345 country: Egypt name: Mohammed A. El-Sawy, PhD role: CONTACT phone: 161314522 email: Dr_sawy@windowslive.com name: PhD role: CONTACT lat: 31.03637 lon: 31.38069 hasResults: False
nctId: NCT06362044 id: P24-120 briefTitle: A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan overallStatus: RECRUITING date: 2023-06-07 date: 2024-12-31 date: 2024-12-31 date: 2024-04-12 date: 2024-04-12 name: AbbVie class: INDUSTRY briefSummary: Most cases of Chronic lymphocytic leukemia (CLL) remain an incurable disease with the goal of therapy being to improve quality of life and to prolong survival. This study will evaluate the participant's related outcomes and experience of CLL in adult participants who are treated in the Japan.
There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice. conditions: Chronic Lymphocytic Leukemia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 89 type: ESTIMATED measure: Percentage of Participants with Undetectable Minimal Residual Disease (uMRD) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Cancer Center Hospital East /ID# 265970 status: RECRUITING city: Kashiwa state: Chiba zip: 277-8577 country: Japan lat: 35.86224 lon: 139.97732 hasResults: False
nctId: NCT06362031 id: H18.Oncology.12-SR1812 briefTitle: A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review overallStatus: WITHDRAWN date: 2023-06-01 date: 2024-04-30 date: 2024-04-30 date: 2024-04-12 date: 2024-04-12 name: AbbVie class: INDUSTRY briefSummary: Acute myeloid leukemia (AML), also referred to as acute myelogenous leukemia or acute non-lymphocytic leukemia, is a relatively rare, yet aggressive, type of cancer. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with AML receiving venetoclax.
There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 10 months. conditions: Acute Myeloid Leukemia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 0 type: ACTUAL measure: Overall Survival (OS) measure: Event-free survival (EFS) measure: Percentage of Participants Achieving Best Overall Response measure: Duration of Response (DoR) measure: Percentage of Participants with Transfusion Independence (TI) measure: Number of Participants with Healthcare Resource Utilization (HRU) sex: ALL minimumAge: 18 Years maximumAge: 89 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06362018 id: MHC/CT/23-24/055 id: MHC/CT/23-24/055, Version No.: type: OTHER domain: Mprex Healthcare Pvt. Ltd. briefTitle: Bioavailability of Three Mitopure Formulations overallStatus: NOT_YET_RECRUITING date: 2024-04-09 date: 2024-05-31 date: 2024-06-30 date: 2024-04-12 date: 2024-04-12 name: Amazentis SA class: INDUSTRY name: Mprex Healthcare Pvt. Ltd. briefSummary: This study's design as an open-label, single-dose, randomized trial that aligns with the objective of characterizing the concentration-time profiles of three Urolithin A (Mitopure) formulations in a controlled setting. The inclusion criteria, stringent fasting requirements, standardized fluid intake and strict dietary restriction protocols ensure homogeneity among the study participants, enhancing the reliability of the outcomes.
Ultimately, this clinical trial aims to contribute valuable insights into the pharmacokinetic behavior of the different Urolithin A formulations, facilitating informed decisions for future developments and applications in the realm of health and wellness. conditions: Healthy Adults studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 36 type: ESTIMATED name: Mitopure (Urolithin A) measure: Plasma concentrations of Urolithin A over time and maximal plasma concentration (Cmax) measure: Exposure to Urolithin A over time measured as area under the curve (AUC) measure: Number of adverse events and serious adverse events throughout the study. sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Lokmanya Medical Research Centre and Hospital city: Pune zip: 411033 country: India name: Dr Ramshyam Agarwal, MD role: CONTACT lat: 18.51957 lon: 73.85535 hasResults: False
nctId: NCT06362005 id: AUAREC2023011-1 briefTitle: The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus acronym: RCT overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2024-10-01 date: 2025-03-01 date: 2024-04-12 date: 2024-04-23 name: Al-Azhar University class: OTHER name: Sphinx university briefSummary: evaluate clinically and biochemically the efficacy of topically applied selenium as complementary or alternative to triamcinolone acetonide 0.1% and tacrolimus 0.1% in patients with oral lichen planus. conditions: Lichen Planus, Oral studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 20 type: ESTIMATED name: Triamcinolone Acetonide 0.1% Oint name: Tacrollimus Topical name: Selenium name: Selenium & Triamcinolone Acetonide 0.1% Oint name: Selenium& Tacrollimus topical measure: to assess a visual analog scale (VAS)of the oral lichen planus lesion measure: to assess The associated Oral Disease Severity Score 3- Glutathione biomarker level as an antioxidant enzyme in saliva by ELISA analysis measure: Biochemical evaluation of salivary Glutathione level using (ELISA) sex: ALL minimumAge: 20 Years maximumAge: 55 Years stdAges: ADULT facility: Alazhar university ,faculty of Dental Medicine city: Assiut zip: 0000 country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False
nctId: NCT06361992 id: BC_SERBIA_2022 briefTitle: Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children overallStatus: COMPLETED date: 2022-03-15 date: 2023-09-15 date: 2024-02-13 date: 2024-04-12 date: 2024-04-15 name: Catalysis SL class: INDUSTRY briefSummary: To verify the efficacy and tolerability of Activated Piroctone Olamine (Blue Cap Foam, label volume 100 ml) by CATALYSIS, S. L. Madrid, applied in the management of all types of dermatitis (atopic, seborrheic, eczema) in patients with significant manifestations of the disease in varying areas of the body of varying extent and to assess differences in individual tolerability and the final effect in a group of selected patients aged 3 to 18 years. conditions: Atopic Dermatitis conditions: Atopic Dermatitis and Related Conditions conditions: Atopic Dermatitis Eczema conditions: Atopic Dermatitis \(AD\) studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 58 type: ACTUAL name: Blue Cap Foam measure: Grade of Patient Tolerability to the investigation product measure: Clinical Improvement of Patients with Dermatitis measure: Clinical assessment of symptoms and sings associated with Dermatitis measure: Evaluation of the therapeutic effect of Blue Cap in paediatric patients with dermatitis. measure: Evaluation of the therapeutic effect of Blue Cap on healing of the skin at the patients sex: ALL minimumAge: 3 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: University of Niš Faculty of Medicine, Department of Dermatology and Venereology, University Clinical Center of Niš city: Niš state: Nišava zip: 18108 country: Serbia lat: 43.32472 lon: 21.90333 facility: City Institute for Skin and Venereal Diseases Belgrade city: Belgrade zip: 11000 country: Serbia lat: 44.80401 lon: 20.46513 facility: University of Belgrade Faculty of Medicine, University Clinical Center of Serbia city: Belgrade zip: 11000 country: Serbia lat: 44.80401 lon: 20.46513 hasResults: False
nctId: NCT06361979 id: A1811 briefTitle: SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2026-05 date: 2024-04-12 date: 2024-04-12 name: Huihua Xiong class: OTHER briefSummary: This study aimed to evaluate the use of SHR-A1811 and bevacizumab in HER2-positive Breast Cancer with brain metastases conditions: Breasr Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: SHR-A1811 name: Bevacizumab measure: CNS-ORR measure: PFS measure: ORR measure: AE sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06361966 id: 2021/00638 briefTitle: Evaluating User Satisfaction and Feasibility of a Remote Model for 3d Scanned and Printed Transtibial Prosthetic Sockets overallStatus: COMPLETED date: 2022-01-11 date: 2023-01-09 date: 2023-01-09 date: 2024-04-12 date: 2024-04-12 name: Tan Tock Seng Hospital class: OTHER name: Prosfit Technologies JSC name: Centre for Allied Health and Pharmacy Excellence (CAPE) briefSummary: The goal of this clinical trial is to investigate the repeatability of application of a fully remote method of manufacturing 3D printing of prosthetic sockets for transtibial amputees, and determine user satisfaction of sockets produced through these methods. The study also aims to evaluate the time and cost effectiveness of this production model.